Concordance in assessments between investigators and blinded independent central review (BICR) in hematology oncology clinical trials: a meta-analysis.

ABSTRACT:

Background

Blinded independent central review (BICR) mitigates assessment bias in oncology trials but imposes significant operational burdens. Its value in hematologic malignancies-where multimodal response criteria reduce reliance on subjective imaging assessments compared to solid tumors-remains unestablished. This meta-analysis evaluates BICR-investigator concordance specifically in hematology trials.

Methods

We systematically identified Phase II/III hematology trials (2014-2024) reporting progression-free survival (PFS) and/or objective response rate (ORR) assessments by both investigators and BICR from PubMed. Agreement was quantified using Pearson/Spearman correlation, pooled hazard ratio ratio (HRR, HRINV/HRBICR) for PFS, and odds ratio ratio for ORR (OddsRR, ORINV/OR

SUBMITTER: Tang X 

PROVIDER: S-EPMC12622372 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature